March 9, 2023 - March 14, 2023

Sudarshan Pharma Industries IPO Review & Recommendations

Dilip Davda recommend to "Avoid" the IPO.

Sudarshan Pharma Industries IPO Review Summary from brokers and analysts

Review By	Apply	May Apply	Neutral	Avoid	Not Rated
Count	0	0	0	1	0
%	0.00	0.00	0.00	100.00	0.00

Sudarshan Pharma Industries IPO Analysis By Brokers/Analysts

Reviewer	Recommendation	Past Reviews
Dilip Davda	Avoid

Sudarshan Pharma Industries IPO Review by Dilip Davda (Avoid)

[Dilip Davda] SPIL which failed to sail through its maiden IPO in June 2019 is trying for the second time for nearly double the amount. It is spending whooping Rs. 7.90 cr. (over 10 times projected for the first try) for this IPO process. It has changed the lead manager for this offer and the list of listed peers. Higher borrowings (Rs. 49.41 cr.), and tax notices of Rs. 7.41 cr. (excluding interest/penalty thereon) raises concern. Though it has posted growth in its financial data, it is fully mirrored including the near-term positives in the asking price. Off late we are witnessing a faded out of fancy for the pharma/healthcare segment post-pandemic. There is no harm in skipping this “High-Risk/Low-Return” bet. Read detail review...

Sudarshan Pharma Industries IPO Review by Members

Sudarshan Pharma Industries IPO Reviews, analysis and views by popular members. Read Sudarshan Pharma Industries Ltd IPO reviews by retail investors to find recommended ipo to buy.

Post Recommendation Manage Your IPO Reviews

Sudarshan Pharma Industries IPO Review Summary by Members

Review By	Apply	May Apply	Neutral	Avoid
Count	1	0	0	5
%	16.67	0.00	0.00	83.33

Member	Review
IPOmentor (200+ Posts)	Avoid any pharma company did not well in last three year. All are 52 week low. March 13, 2023 4:49:51 PM
ShethDemat	Apply for Long Term at Upper Price Band Good sales volume and profit. Established in 2008. Alleged fraud and hawala charges are baseless and regulatory bodies like ED, SEBI & NSE/BSE are there to watch it. The accusers must approach ED and SEBI with evidences. March 10, 2023 12:35:17 AM
Vasantrai	Avoid Full bogus company. Its a hawala company and this IPO is to rotate hawala funds. Their revenue is completely fake and they are doing shadow business in the name of Pharma. Close to 40-50% revenue is fake March 8, 2023 2:58:50 PM
Alert Fraud	Avoid Dummy company or false company is an entity created to serve as a front or cover for one or more companies. Please should be careful to Invest. No proper Manufacturing unit and Products. 2019 also planned to issue IPO but failed. 1 March 8, 2023 1:24:26 PM
RajaBanks	Avoid Debt. IPO expenses are suspicious. Change in LM is a big red flag. Balance sheet states money leaking towards bogus expenses. 1 March 4, 2023 3:56:22 PM
IPO LEADER IPO Mentor (800+ Posts, 400+ Likes)	Avoid Avoid due to high debt 1 March 2, 2023 10:12:42 AM

Post Recommendation Manage Recommendations

Note:

The recommendations or analysis of public issues posted above expresses the views of its author and does not represent the views of Chittorgarh.com or its staff.
We reserve the right to remove any objectionable post without providing a reason.